Forbion Capital Fund IV Cooperatief U.A.'s Form 4 filing
NewAmsterdam Pharma Co N.V. (NAMS) · filed Nov 19, 2024
- Accession no.
- 0000950170-24-128607
- Filed
- Nov 19, 2024, 4:15 PM ET
- Trade date
- Nov 15-18, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $1.05M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Forbion Capital Fund IV Cooperatief U.A.CIK 0001823747 | 10% Owner |
| Forbion Growth Opportunities Fund I Cooperatief U.A.CIK 0001911047 | 10% Owner |
| Forbion Growth Management B.V.CIK 0001918318 | 10% Owner |
| Forbion IV Management B.V.CIK 0002005384 | 10% Owner |
| ForGrowth NAP B.V.CIK 0002005407 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 15, 2024 | Ordinary Shares | SSaleDisposed | −8,530 | $25.02 | −$213,435.95 | 11,812,033 | Indirect | |
| Nov 18, 2024 | Ordinary Shares | SSaleDisposed | −33,273 | $25.08 | −$834,440.26 | 11,778,760 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.